Dermatology Treatments and their Effects on Patch Testing

Authors

  • Sophia Colantonio, MD, FRCPC The Ottawa Hospital, Civic Campus, Ottawa, ON, Children’s Hospital of Eastern Ontario, Ottawa, ON, Vital Medical Centre, Ottawa, ON

DOI:

https://doi.org/10.58931/cdt.2024.53127

Abstract

Patients are often sent for patch testing to rule out allergic contact dermatitis, but it is a clinical conundrum of what to do when they are on systemic agents. The clinical question is, should the systemic agents be held for 4-5 half-lives and then patch tested to ensure there is no blunting of the immune system? The reality is that in this population without systemic treatments, patients are seldom clear enough to patch test. Their backs are covered in dermatitis and testing runs the risk of eliciting an uninterpretable “angry back”. The other consideration is patients’ strong preference to remain on systemic medications that control their significant itch, rash and associated sequelae. In an ideal world, it would best to patch test patients prior to the initiation of a systemic agent but clinically this is not always feasible. 

We will explore various clinical scenarios involving patch testing and discuss the advice the dermatologist should provide patients regarding holding their medications.

Author Biography

Sophia Colantonio, MD, FRCPC, The Ottawa Hospital, Civic Campus, Ottawa, ON, Children’s Hospital of Eastern Ontario, Ottawa, ON, Vital Medical Centre, Ottawa, ON

Dr. Sophia Colantonio is a board-certified dermatologist in Canada and the United States. She is currently practicing at the Ottawa Hospital Civic Campus where she runs specialized clinics in patch testing for allergic contact dermatitis, biologics for complex medical dermatological conditions and pigmented lesions for high-risk melanoma patients.  In 2024, she founded Factor Dermatology (www.factordermatology.ca) to provide innovative and accessible dermatology care in the Ottawa community. It is opening in October 2024. 

References

Goldenberg A, Ehrlich A, Machler BC, et al. Patch test clinic start-up: from basics to pearls. Dermatitis. 2020 Sep/Oct;31(5):287-96.

Fisher’s Contact Dermatitis, 7th edition. Joseph F. Fowler and Matthew J. Zirwas (eds). Raleigh, NC: PMPH USA, 2018.

Mufti A, Lu JD, Sachdeva M, et al. Patch testing during immunosuppressive therapy: a systematic review. Dermatitis. 2021;32(6):365-74.

Anveden I, Lindberg M, Andersen KE, et al. Oral prednisone suppresses allergic but not irritant patch test reactions in individuals hypersensitive to nickel. Contact Dermatitis. 2004;50(5):298–303.

Olupona T, Scheinman P. Successful patch testing despite concomitant low-dose prednisone use. Dermatitis. 2008;19(2):117-8.

Hamann D, Zirwas M. Successful patch testing of a patient receiving anti-interleukin-17 therapy with secukinumab: a case report. Contact Dermatitis. 2017;76(6):378–9.

Johnson H, Adler BL, Yu J. Dupilumab for allergic contact dermatitis: an overview of Its use and impact on patch testing. Cutis. 2022 May;109(5):265-7.

Raffi J, Botto N. Patch testing and allergen-specific inhibition in a patient taking dupilumab. JAMA Dermatol. 2019;155(1):120–1.

Bocquel S, Soria A, Raison-Peyron N, et al. Impact of dupilumab on patch test results and allergic contact dermatitis: A prospective multicenter study. J Am Acad Dermatol. 2024 Mar;90(3):512-20.

Dupilumab. Lexi-Drugs. UpToDate Lexidrug. UpToDate Inc. https://online.lexi.com. Accessed 2 Sept 2024.

Mainville L, Veillette H, Houle MC. Sequential patch testing in a patient treated with dupilumab then with upadacitinib: Differences in patch test results as well as in disease control. Contact Dermatitis. 2023 May;88(5):402-4.

Upadacitinib. Lexi-Drugs. UpToDate Lexidrug. UpToDate Inc. https://online.lexi.com. Accessed 2 Sept 2024.

Published

2024-10-02

How to Cite

1.
Colantonio S. Dermatology Treatments and their Effects on Patch Testing. Can Dermatol Today [Internet]. 2024 Oct. 2 [cited 2024 Dec. 6];5(3):29–31. Available from: https://canadiandermatologytoday.com/article/view/5-3-Colantonio

Issue

Section

Articles